Key Takeaways:
- Orion Corporation partners with Newel Health to license groundbreaking digital therapeutic (DTx), ODD-403, aimed at revolutionizing chronic pain treatment.
- ODD-403 leverages virtual reality to offer an immersive, gamified therapeutic experience, marking significant advancements in managing chronic pain.
- The partnership underscores a strategic move towards integrating digital innovation in healthcare, with Newel Health poised to further develop and commercialize ODD-403 globally.
In an era where digital innovation continues to redefine healthcare landscapes, a pioneering partnership emerges, promising to transform the way chronic pain is managed. Orion Corporation, a beacon of well-being and pharmaceutical ingenuity, has entered into a licensing agreement with digital health leader Newel Health. This collaboration centers around ODD-403, dubbed “Rohkea,” a digital therapeutic (DTx) designed to confront chronic pain and the associated fear of movement and re-injury head-on.
Bridging the Digital Divide in Pain Management
The venture between Orion and Newel Health represents a significant leap forward in digital medicine, particularly in the realm of chronic pain management. ODD-403’s development underscores a commitment to harnessing technological advancements to address pressing medical needs. “Newel is one of the frontrunners in digital therapeutic (DTx) applications, and we are pleased to have them as our partner in this indication area,” remarks Sammeli Liikkanen, Director of Digital Medicine at Orion Corporation. This partnership not only highlights a shared vision for healthcare innovation but also sets a new standard for patient-centered treatment modalities.
ODD-403: A New Horizon in Therapeutics
ODD-403 stands out as a software as a medical device (SaMD), meticulously crafted for virtual reality (VR) platforms. It introduces patients to an immersive world where gamified therapeutic sessions are designed to mitigate chronic pain and alleviate the fear of movement. This novel approach to treatment is backed by the VIRPI study, which showcases ODD-403’s effectiveness in reducing kinesiophobia scores and enhancing patients’ quality of life.
Gerry Chillè, Chief Strategy Officer at Newel Health, expresses enthusiasm for the project: “Orion Corporation’s commitment to address medical needs through digital innovation has been the driving force behind our ongoing collaborations. Today we are excited to welcome ODD-403 under our wing for further development and introduction to market, adding Virtual Reality modalities to our growing portfolio of partner-ready DTx solutions.”
A Synergistic Partnership for the Future
The alliance between Orion and Newel Health is poised to redefine therapeutic interventions in the digital age. By granting Newel exclusive global rights to develop, manufacture, and commercialize ODD-403, the partnership catalyzes the expansion of digital therapeutics into mainstream healthcare. Orion’s venture into digital medicine, particularly through the development of ODD-403, aligns with its broader mission to build well-being and address complex medical challenges with innovative solutions.
Conclusion: Pioneering Pain Management in the Digital Era
As digital technologies continue to permeate the healthcare sector, the collaboration between Orion Corporation and Newel Health marks a pivotal moment in the journey toward modernizing pain management. ODD-403 embodies the potential of digital therapeutics to offer more accessible, effective, and patient-centric treatment options. This partnership not only paves the way for advancements in chronic pain therapy but also signals a broader shift towards embracing digital innovation in addressing global health challenges.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at pitch@businesstoday.news to get started!
